The global cancer biopsy market size was estimated to be USD 30.23 billion in 2023 and is expected to reach at USD 70.85 billion by 2034 with a CAGR of 8.05% during the forecast period 2024-2034. Rising prevalence of oncology cases, growing elderly population, increasing advancements in biopsy techniques, increasing demand for early patient detection, surge in technological advancements, heightened research & development efforts, rising focus on creating more accurate & effective biopsy procedures, and surge in the introduction of cancer biopsy devices are some of the key factors boosting the market growth.
Surge in the introduction of cancer biopsy devices is predicted to grow at the fastest CAGR during the forecast period. A cancer biopsy is a medical process involving the extraction of a small tissue sample from an area in the body that appears suspicious or abnormal. This sample is then examined under a microscope to ascertain the presence of cancer cells and, if detected, to classify the specific type of cancer involved. The primary objective of a biopsy is to provide accurate information about the nature of the tissue and aid in the diagnosis and subsequent treatment planning for the patient. For instance, in September 2023, Limaca Medical has disclosed that its Precision GI Endoscopic Ultrasound (EUS) Biopsy Device has obtained 510(k) clearance from the U.S. Food and Drug Administration (FDA). This development comes after Limaca previously secured FDA Breakthrough Device Designation for its Precision GI.
By type, tissue biopsy was the highest revenue-grossing segment in the global cancer biopsy market in 2023 owing to the increasing adoption of various applications for cancer diagnosis, a rise in research activities assessing the safety & efficacy of these approaches, and surge in advancements specifically aimed at improving tissue biopsy procedures. Additionally, liquid biopsies is predicted to grow at the fastest CAGR during the forecast period owing to the integration of AI technology with liquid biopsy is on the rise to enhance the analysis of DNA mutations. Physicians are increasingly favoring liquid biopsy due to its capacity to provide comprehensive disease snapshots from both primary and distant tumor sites. This approach is particularly utilized in personalized medicine treatments, where tumor markers are sampled repeatedly to modify therapy according to the patient's response to the treatment. For instance, in April 2023, South Korean company GC Genome Corporation has revealed a partnership with the Korea Advanced Institute of Science and Technology (KAIST), underscoring the introduction of the company's advanced liquid biopsy technology utilizing artificial intelligence for improved analysis of DNA mutations.
By product, kits & consumables was the highest revenue-grossing segment in the global cancer biopsy market in 2023 as their indispensability throughout different biopsy stages, there is a notable increase in investments by major industry players. The growing global patient population emphasizes the demand for consumables and kits that are not only efficient but also accurate and swift. Additionally, instruments is predictec to grow at the fastest CAGR during the forecast period. Numerous emerging manufacturers are focusing on introducing instruments designed to improve biopsies conducted through endoscopy. For instance, in December 2022, The single-use Cervical Rotating Biopsy Punch is a new device offered by Summit Medical LLC. This new addition is designed to facilitate time-sensitive procedures such as cancer diagnosis.
By application, breast cancer was the highest revenue-grossing segment in the global cancer biopsy market in 2023 owing to the high prevalence of breast cancer, an increasing population of individuals suspected of having the disease undergoing mandatory microscopic analysis of breast tissue, and rising demand for either needle biopsy or surgical biopsy procedures to acquire tissue for subsequent microscopic examination. Additionally, prostate cancer is predicted to grow at the fastest CAGR during the forecast period owing to the increasing incidence of prostate cancer, accompanied by a heightened emphasis on creating innovative products and the continuous introduction of advanced devices. For instance, in July 2022, BillionToOne, Inc., a molecular diagnostics company committed to making potent and precise tests available to everyone, has introduced its initial oncology liquid biopsy products, namely Northstar Select and Northstar Response.
North America region is anticipated for the highest revenue share during the forecast period owing to a heightened emphasis on creating new kits tailored for rapid diagnostic applications, accompanied by continuous technological advancements and increase in product approvals. For instance, in August 2022, Guardant Health has received approval from the U.S. FDA for its Guardant360 CDx liquid biopsy test, designated as a companion diagnostic (CDx). This approval allows the selection of patients with unresectable or metastatic non-small cell lung cancer (NSCLC) carrying activating HER2 (ERBB2) mutations in their tumors for treatment with ENHERTU (fam-trastuzumab deruxtecan-nxki). Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the rising trend in the adoption of advanced liquid biopsy techniques, increasing prevalence of lung cancer cases, surge in awareness among both patients & healthcare professionals, and the continuous introduction of new products. For instance, in May 2023, Labcorp has introduced the Labcorp Plasma Focus, a novel liquid biopsy test designed for the targeted therapy selection of patients dealing with advanced or metastatic solid tumors. This test enables treating oncologists to assess circulating cell-free DNA (cfDNA) released by tumor cells, facilitating improved patient care management through personalized and targeted therapy plans.
Surge in the introduction of cancer biopsy devices is predicted to grow at the fastest CAGR during the forecast period. A cancer biopsy is a medical process involving the extraction of a small tissue sample from an area in the body that appears suspicious or abnormal. This sample is then examined under a microscope to ascertain the presence of cancer cells and, if detected, to classify the specific type of cancer involved. The primary objective of a biopsy is to provide accurate information about the nature of the tissue and aid in the diagnosis and subsequent treatment planning for the patient. For instance, in September 2023, Limaca Medical has disclosed that its Precision GI Endoscopic Ultrasound (EUS) Biopsy Device has obtained 510(k) clearance from the U.S. Food and Drug Administration (FDA). This development comes after Limaca previously secured FDA Breakthrough Device Designation for its Precision GI.
By type, tissue biopsy was the highest revenue-grossing segment in the global cancer biopsy market in 2023 owing to the increasing adoption of various applications for cancer diagnosis, a rise in research activities assessing the safety & efficacy of these approaches, and surge in advancements specifically aimed at improving tissue biopsy procedures. Additionally, liquid biopsies is predicted to grow at the fastest CAGR during the forecast period owing to the integration of AI technology with liquid biopsy is on the rise to enhance the analysis of DNA mutations. Physicians are increasingly favoring liquid biopsy due to its capacity to provide comprehensive disease snapshots from both primary and distant tumor sites. This approach is particularly utilized in personalized medicine treatments, where tumor markers are sampled repeatedly to modify therapy according to the patient's response to the treatment. For instance, in April 2023, South Korean company GC Genome Corporation has revealed a partnership with the Korea Advanced Institute of Science and Technology (KAIST), underscoring the introduction of the company's advanced liquid biopsy technology utilizing artificial intelligence for improved analysis of DNA mutations.
By product, kits & consumables was the highest revenue-grossing segment in the global cancer biopsy market in 2023 as their indispensability throughout different biopsy stages, there is a notable increase in investments by major industry players. The growing global patient population emphasizes the demand for consumables and kits that are not only efficient but also accurate and swift. Additionally, instruments is predictec to grow at the fastest CAGR during the forecast period. Numerous emerging manufacturers are focusing on introducing instruments designed to improve biopsies conducted through endoscopy. For instance, in December 2022, The single-use Cervical Rotating Biopsy Punch is a new device offered by Summit Medical LLC. This new addition is designed to facilitate time-sensitive procedures such as cancer diagnosis.
By application, breast cancer was the highest revenue-grossing segment in the global cancer biopsy market in 2023 owing to the high prevalence of breast cancer, an increasing population of individuals suspected of having the disease undergoing mandatory microscopic analysis of breast tissue, and rising demand for either needle biopsy or surgical biopsy procedures to acquire tissue for subsequent microscopic examination. Additionally, prostate cancer is predicted to grow at the fastest CAGR during the forecast period owing to the increasing incidence of prostate cancer, accompanied by a heightened emphasis on creating innovative products and the continuous introduction of advanced devices. For instance, in July 2022, BillionToOne, Inc., a molecular diagnostics company committed to making potent and precise tests available to everyone, has introduced its initial oncology liquid biopsy products, namely Northstar Select and Northstar Response.
North America region is anticipated for the highest revenue share during the forecast period owing to a heightened emphasis on creating new kits tailored for rapid diagnostic applications, accompanied by continuous technological advancements and increase in product approvals. For instance, in August 2022, Guardant Health has received approval from the U.S. FDA for its Guardant360 CDx liquid biopsy test, designated as a companion diagnostic (CDx). This approval allows the selection of patients with unresectable or metastatic non-small cell lung cancer (NSCLC) carrying activating HER2 (ERBB2) mutations in their tumors for treatment with ENHERTU (fam-trastuzumab deruxtecan-nxki). Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the rising trend in the adoption of advanced liquid biopsy techniques, increasing prevalence of lung cancer cases, surge in awareness among both patients & healthcare professionals, and the continuous introduction of new products. For instance, in May 2023, Labcorp has introduced the Labcorp Plasma Focus, a novel liquid biopsy test designed for the targeted therapy selection of patients dealing with advanced or metastatic solid tumors. This test enables treating oncologists to assess circulating cell-free DNA (cfDNA) released by tumor cells, facilitating improved patient care management through personalized and targeted therapy plans.
Segmentation: Cancer Biopsy Market Report 2023 - 2034
Cancer Biopsy Market Analysis & Forecast by Type 2023 - 2034 (Revenue USD Bn)
- Tissue Biopsies
- Surgical Biopsies
- Needle Biopsies
- Core Needle Biopsy (CNB)
- Fine Needle Aspiration (FNA)
- Liquid Biopsies
- Others
Cancer Biopsy Market Analysis & Forecast by Product 2023 - 2034 (Revenue USD Bn)
- Kits & Consumables
- Instruments
- Services
Cancer Biopsy Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- Lung Cancers
- Blood Cancers
- Colorectal Cancer
- Prostate Cancers
- Liver Cancers
- Pancreatic Cancers
- Cervical Cancers
- Breast Cancer
- Skin Cancers
- Ovarian Cancers
- Kidney Cancers
- Others
Cancer Biopsy Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Cancer Biopsy Market: Type Estimates & Trend Analysis
8. Cancer Biopsy Market: Product Estimates & Trend Analysis
9. Cancer Biopsy Market: Application Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Cancer Biopsy Market
12. Europe Global Cancer Biopsy Market
13. Asia Pacific Global Cancer Biopsy Market
14. Latin America Global Cancer Biopsy Market
15. MEA Global Cancer Biopsy Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Lucence Diagnostics Pte. Ltd.
- Illumina Inc.
- Epigenomics AG
- BD (Becton
- Dickinson and Company)
- Biodesix (Integrated Diagnostics)
- Hologic Inc.
- HelioHealth (Laboratory for Advanced Medicine)
- Qiagen N.V.
- Thermo Fisher Scientific Inc.
- Biocept Inc.
- F. Hoffmann-La Roche Ltd.
- Freenome Holdings Inc.
- Genesystems Inc. (Genesys Biolabs)
- Danaher
- Chronix Biomedical Inc.
- Exact Sciences Corporation
- Personal Genome Diagnostics Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | March 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 30.23 Billion |
| Forecasted Market Value ( USD | $ 70.85 Billion |
| Compound Annual Growth Rate | 8.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 18 |
